Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis <2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract format and assignment number: Poster presentation 0398
Date: Sunday October 26, 2025
Presenting author: S Gulla (USA)
This abstract used the CARRA Registry to investigate the efficacy of TNF inhibitors in children with non-sJIA <2 years and found that those children presented with higher baseline disease activity but demonstrated sustained improvements in all disease activity measures by 12 months, suggesting early TNFi therapy has a significant impact on disease course.
Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
Abstract format and assignment number: Poster presentation 0409
Date: Sunday, October 26, 2025
Presenting author: J Harris (USA)
Among 584 children with JIA over >1000 visits, active arthritis was present in 31% of patients though among those with inactive disease by cJADAS-10, 34% reported functional limitations and 37.5% reported pain, suggesting the importance of collection of both patient-reported outcomes (PROs) and disease activity measures when assessing arthritis activity in children with JIA.
Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: results from a Pooled Analysis of Two Prospective Trials
Abstract format and assignment number: Oral presentation 1671
Date: Monday, October 27, 2025
Presenting author: A Grom (USA)
Among 39 patients with MAS in Still’s disease with inadequate response to high-dose glucocorticoids or worsening clinical status, emapalumab treatment was associated with consistent clinical remission in ~55-60% of patients with different MAS presentations.
S100B in Childhood-onset Systemic Lupus Erythematosus: Associations with Disease Features, Interferon Levels, and Cognitive Functioning
Abstract format and assignment number: Oral abstract 1742
Date: Tuesday, October 28, 2025
Presenting author: G Ramanathan (Canada)
49 participants with cSLE and 40 controls completed cognitive testing and collection of S100B, interferon alpha and gamma testing. In contrast to adult onset SLE, serum S100B was not associated with cognitive functioning in cSLE with significant inverse associations noted between type I and type II interferon.
Preceding Mental Health Diagnosis Does Predict Eventual Neuropsychiatric Disease in Childhood-Onset Systemic Lupus Erythematosus
Abstract format and assignment number: Oral presentation 1744
Date: Tuesday, October 28, 2025
Presenting author: E Ogbu (USA)
Among >8000 patients with childhood-onset SLE, preceding mood disorders such as depression and anxiety within 18 months prior to SLE diagnosis was associated with a >2-fold risk in the subsequent development of neuropsychiatric lupus.
Tofacitinib in Juvenile Spondyloarthropathy: Clinical Efficacy, Impact on Biomarkers, and Comparison with Adalimumab
Abstract format and assignment number: Oral abstract 2676
Date: Wednesday, October 29, 2025
Presenting author: R Chatterjee (India)
In a study including 53 patients with JSpA (29 on tofacitinib and 24 on ADA), both groups showed similar improvements in disease activity (measured by both the JSpADA score and BASDAI), similar improvements in the reduction in inflammatory markers, and similar safety profile.
High Health Care Utilization Preceding diagnosis of Juvenile Idiopathic Arthritis
Abstract format and assignment number: Oral abstract 2680
Date: Wednesday, October 29, 2025
Presenting author: A Costello (USA)
Using large nationwide U.S. data, 10,021 children were identified with new JIA in a 1-year period and had significantly higher healthcare utilization, including healthcare encounters and inpatient and emergency room or urgent care encounters, compared to healthy controls. This suggests there may be opportunities, particularly in a primary care setting, to identify JIA earlier.
Danny Soulsby
Danny is an Assistant Professor of Pediatrics in the Division of Pediatric Rheumatology at the University of California, San Francisco. His research interests focus on health disparities in juvenile idiopathic arthritis and pediatric systemic lupus erythematosus.
Danny is a member of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and is currently the Early Career Committee Vice Chair.